ASO Author Reflections: TP53 and PKD Co-mutations Were Associated with Poorer Prognoses in Patients with Resected EGFR-Mutated Lung Adenocarcinoma
ASO Author Reflections
- 20 Downloads
Hao Long and Di-Han Liu have no conflicts of interest to disclose.
- 4.Shepherd F, Lacas B, Le Teuff G, et al. Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2017;35(18):2018–27.CrossRefGoogle Scholar
© Society of Surgical Oncology 2019